Evidence map›Paper›PMID 34673821›Full record

Observational studyPloS one2021

Mortality in association with antipsychotic medication use and clinical outcomes among geriatric psychiatry outpatients with COVID-19.

Bienvenida Austria, Rehana Haque, Sukriti Mittal, Jamie Scott, Aninditha Vengassery, Daniel Maltz, Wentian Li, Blaine Greenwald, Yun Freudenberg-Hua

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Bienvenida AustriaDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.
Rehana HaqueDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.
Sukriti MittalDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.
Jamie ScottDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.
Aninditha VengasseryDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.
Daniel MaltzInformation Services, Product Services and Management, Northwell Health, Lake Success, NY, United States of America.
Wentian LiCenter for Genomics and Human Genetics, The Feinstein Institutes for Medical Research, Manhasset, NY, United States of America.
Blaine GreenwaldDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.
Yun Freudenberg-HuaDivision of Geriatric Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, United States of America.ORCID 0000-0003-3398-7270
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell · USFeinstein Institute for Medical Research · USNorthwell Health · US

Funding

Identification of Risk Genes SupplementK08AG054727 · NIA · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI FREUDENBERG-HUA, YUN · 2017 to 2022
$739k
NIA NIH HHS K08 AG054727
6 · The paper itself

Abstract

objectivesOlder adults are particularly vulnerable to the negative consequences of antipsychotic exposure and are disproportionally affected by higher mortality from coronavirus disease 2019 (COVID-19). Our goal was to determine whether concurrent antipsychotic medication use was associated with increased COVID-19 mortality in older patients with preexisting behavioral health problems. We also report on findings from post-COVID follow-ups.

designRetrospective observational study.

participantsOutpatients at a geriatric psychiatric clinic in New York City. MEASUREMENTS: Demographic and clinical data including medication, diagnosis and Clinical Global Impression Severity (CGI-S) scales on outpatients who had COVID-19 between February 28th and October 1st 2020 were extracted from the electronic health records (EHR) from the hospital.

resultsA total of 56 patients were diagnosed with COVID-19 (mean age 76 years; median age 75 years) and 13 (23.2%) died. We found an increased mortality risk for patients who were prescribed at least one antipsychotic medication at the time of COVID-19 infection (Fisher's exact test P = 0.009, OR = 11.1, 95% confidence interval: 1.4-96.0). This result remains significant after adjusting for age, gender, housing context and dementia (Logistic regression P = 0.035, Beta = 2.4). Furthermore, we found that most patients who survived COVID-19 (88.4%) recovered to pre-COVID baseline in terms of psychiatric symptoms. Comparison of pre- and post-COVID assessments of CGI-S for 33 patients who recovered from COVID-19 were not significantly different.

conclusionWe observed a higher COVID-19 mortality associated with concurrent antipsychotics use in older patients receiving behavioral health services. The majority of patients in our geriatric clinic who recovered from COVID-19 appeared to return to their pre-COVID psychiatric function. More precise estimates of the risk associated with antipsychotic treatment in older patients with COVID-19 and other underlying factors will come from larger datasets and meta-analyses.

Indexed as

Mental DisordersOutpatientsSARS-CoV-2AgedAged, 80 and overAntipsychotic AgentsCOVID-19FemaleGeriatric PsychiatryHumansMaleNew York CityRetrospective StudiesAntipsychotic Agents

Identifiers

PMID34673821
PMCPMC8530340
OpenAlexW3206970571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.